The integration of harm reduction services in the Veterans Health Administration (VHA): a qualitative analysis of barriers and facilitators

References

• Davis TM, Bush KR, Kivlahan DR, Dobie DJ, Bradley KA. Screening for substance abuse and psychiatric disorders among women patients in a VA Health Care System. Psychiatr Serv. 2003;54(2):214–8. doi:10.1176/appi.ps.54.2.214.
   PubMed Web of Science ®Google Scholar
• Hawkins EJ, Grossbard J, Benbow J, Nacev V, Kivlahan DR. Evidence-based screening, diagnosis, and treatment of substance use disorders among veterans and military service personnel. Mil Med. 2012;177(8 Suppl):29–38. doi:10.7205/milmed-d-12-00125.
   PubMed Web of Science ®Google Scholar
• Hoggatt KJ, Harris AHS, Washington DL, Williams EC. Prevalence of substance use and substance-related disorders among US Veterans Health Administration patients. Drug Alcohol Depend. 2021;225:108791. doi:10.1016/j.drugalcdep.2021.108791.
   PubMed Web of Science ®Google Scholar
• Lan C-W, Fiellin DA, Barry DT, Bryant KJ, Gordon AJ, Edelman EJ, Gaither JR, Maisto SA, Marshall BDL. The epidemiology of substance use disorders in US Veterans: a systematic review and analysis of assessment methods. Am J Addict. 2016;25(1):7–24. doi:10.1111/ajad.12319.
   PubMed Web of Science ®Google Scholar
• Teeters JB, Lancaster CL, Brown DG, Back SE. Substance use disorders in military veterans: prevalence and treatment challenges. Subst Abuse Rehabil. 2017;8:69–77. doi:10.2147/SAR.S116720.
   PubMed Web of Science ®Google Scholar
• Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and geographic patterns in drug and synthetic opioid overdose deaths - United States, 2013-2019. MMWR Morb Mortal Wkly Rep. 2021;70(6):202–7. doi:10.15585/mmwr.mm7006a4.
   PubMed Web of Science ®Google Scholar
• Seal KH, Shi Y, Cohen G, Cohen BE, Maguen S, Krebs EE, Neylan TC. Association of mental health disorders with prescription opioids and high-risk opioid use in US Veterans of Iraq and Afghanistan. JAMA. 2012;307(9):940–7. doi:10.1001/jama.2012.234.
   PubMed Web of Science ®Google Scholar
• Ronan MV, Herzig SJ. Hospitalizations related to opioid abuse/dependence and associated serious infections increased sharply, 2002-12. Health Aff (Millwood)). 2016;35(5):832–7. doi:10.1377/hlthaff.2015.1424.
   PubMed Web of Science ®Google Scholar
• Zibbell JE, Asher AK, Patel RC, Kupronis B, Iqbal K, Ward JW, Holtzman D. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2018;108(2):175–81. doi:10.2105/AJPH.2017.304132.
   PubMed Web of Science ®Google Scholar
• Des Jarlais DC. Harm reduction in the USA: the research perspective and an archive to David Purchase. Harm Reduct J. 2017;14(1):51. doi:10.1186/s12954-017-0178-6.
   PubMed Web of Science ®Google Scholar
• Hawk M, Coulter RWS, Egan JE, Fisk S, Reuel Friedman M, Tula M, Kinsky S. Harm reduction principles for healthcare settings. Harm Reduct J. 2017;14(1):70. doi:10.1186/s12954-017-0196-4.
   PubMedGoogle Scholar
• Bernard CL, Owens DK, Goldhaber-Fiebert JD, Brandeau ML. Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: a model-based analysis. PLoS Med. 2017;14(5):e1002312. doi:10.1371/journal.pmed.1002312.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. 2019. Syringe Services Programs. In. https://www.cdc.gov/ssp/index.html.
   Google Scholar
• Fernandes RM, Cary M, Duarte G, Jesus G, Alarcão J, Torre C, Costa S, Costa J, Carneiro AV. Effectiveness of needle and syringe Programmes in people who inject drugs - An overview of systematic reviews. BMC Public Health. 2017;17(1):309. doi:10.1186/s12889-017-4210-2.
   PubMed Web of Science ®Google Scholar
• Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006;41(6-7):777–813. doi:10.1080/10826080600669579.
   PubMed Web of Science ®Google Scholar
• Mueller SR, Walley AY, Calcaterra SL, Glanz JM, Binswanger IA. A review of opioid overdose prevention and naloxone prescribing: implications for translating community programming into clinical practice. Subst Abus. 2015;36(2):240–53. doi:10.1080/08897077.2015.1010032.
   PubMed Web of Science ®Google Scholar
• Winhusen T, Wilder C, Lyons MS, Theobald J, Kropp F, Lewis D. Evaluation of a personally-tailored opioid overdose prevention education and naloxone distribution intervention to promote harm reduction and treatment readiness in individuals actively using illicit opioids. Drug Alcohol Depend. 2020;216:108265. doi:10.1016/j.drugalcdep.2020.108265.
   PubMed Web of Science ®Google Scholar
• Hagan H, McGough JP, Thiede H, Hopkins S, Duchin J, Alexander ER. Reduced injection frequency and increased entry and retention in drug treatment associated with needle-exchange participation in Seattle drug injectors. J Subst Abuse Treat. 2000;19(3):247–52. doi:10.1016/s0740-5472(00)00104-5.
   PubMed Web of Science ®Google Scholar
• Taylor JL, Johnson S, Cruz R, Gray JR, Schiff D, Bagley SM. Integrating harm reduction into outpatient opioid use disorder treatment settings: harm reduction in outpatient addiction treatment. J Gen Intern Med. 2021;36(12):3810–9. doi:10.1007/s11606-021-06904-4.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Collins FS. The role of science in addressing the opioid crisis. N Engl J Med. 2017;377(4):391–4. doi:10.1056/NEJMsr1706626.
   PubMed Web of Science ®Google Scholar
• Burris S. Where next for opioids and the law? Despair, harm reduction, lawsuits, and regulatory reform. Public Health Rep. 2018;133(1):29–33. doi:10.1177/0033354917743500.
   PubMed Web of Science ®Google Scholar
• Nadelmann E, LaSalle L. Two steps forward, one step back: current harm reduction policy and politics in the United States. Harm Reduct J. 2017;14(1):37. doi:10.1186/s12954-017-0157-y.
   PubMed Web of Science ®Google Scholar
• Assistant Under Secretary for Clinical Services, D. o. V. A. 24 May, 2021. Interim Guidance on Syringe Service Programs (SSPs) in the Veterans Health Administration (VHA) (VIEWS# 05009598).
   Google Scholar
• Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019., H.R. 6157 2018.
   Google Scholar
• Maguire E. 2021. Providing clean syringes to Veterans who inject drugs. In (Vol. 2021). https://blogs.va.gov/VAntage/89943/providing-veterans-inject-drugs-clean-syringes/:. Veterans Affairs Vantage Point.
   Google Scholar
• Office, H. P. 2021. HHS secretary becerra announces new overdose prevention strategy. In. https://www.hhs.gov/about/news/2021/10/27/hhs-secretary-becerra-announces-new-overdose-prevention-strategy.html.
   Google Scholar
• Feldstein AC, Glasgow RE. A practical, robust implementation and sustainability model (PRISM) for integrating research findings into practice. Jt Comm J Qual Patient Saf. 2008;34(4):228–43. doi:10.1016/s1553-7250(08)34030-6.
   PubMedGoogle Scholar
• Waltz TJ, Powell BJ, Fernández ME, Abadie B, Damschroder LJ. Choosing implementation strategies to address contextual barriers: diversity in recommendations and future directions. Implementation Sci. 2019;14(1):42. doi:10.1186/s13012-019-0892-4.
   PubMed Web of Science ®Google Scholar
• Grimshaw JM, Shirran L, Thomas R, Mowatt G, Fraser C, Bero L, Grilli R, Harvey E, Oxman A, O’Brien MA. Changing provider behavior: an overview of systematic reviews of interventions. Med Care. 2001;39(8 Suppl 2):II–2-II-45. doi:10.1097/00005650-200108002-00002.
   Web of Science ®Google Scholar
• Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implementation Sci. 2011;6(1):42. doi:10.1186/1748-5908-6-42.
   PubMed Web of Science ®Google Scholar
• Norms, C. o. t. S. o. C. B. H. S., Board on Behavioral, C. g., and Sensory Sciences, Education, D. o. B. a. S. S. a., & National Academies of Sciences, E. g., and Medicine. 2016. Ending discrimination against people with mental and substance use disorders: the evidence for stigma change. In. doi:NBK384915.
   Google Scholar
• Harvey L, Boudreau J, Sliwinski SK, Strymish J, Gifford AL, Hyde J, Linsenmeyer K, Branch-Elliman W. Six moments of infection prevention in injection drug use: an educational toolkit for clinicians. Open Forum Infect Dis. 2022;9(2):ofab631. doi:10.1093/ofid/ofab631.
   PubMed Web of Science ®Google Scholar
• Bearnot B, Mitton JA, Hayden M, Park ER. Experiences of care among individuals with opioid use disorder-associated endocarditis and their healthcare providers: results from a qualitative study. J Subst Abuse Treat. 2019;102:16–22. doi:10.1016/j.jsat.2019.04.008.
   PubMed Web of Science ®Google Scholar
• Cheetham A, Picco L, Barnett A, Lubman DI, Nielsen S. The impact of stigma on people with opioid use disorder, opioid treatment, and policy. Subst Abuse Rehabil. 2022;13:1–12. doi:10.2147/SAR.S304566.
   PubMed Web of Science ®Google Scholar
• Kelly JF, Westerhoff CM. Does it matter how we refer to individuals with substance-related conditions? A randomized study of two commonly used terms. Int J Drug Policy. 2010;21(3):202–7. doi:10.1016/j.drugpo.2009.10.010.
   PubMed Web of Science ®Google Scholar